FR2940652B1 - Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique - Google Patents

Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique

Info

Publication number
FR2940652B1
FR2940652B1 FR0807475A FR0807475A FR2940652B1 FR 2940652 B1 FR2940652 B1 FR 2940652B1 FR 0807475 A FR0807475 A FR 0807475A FR 0807475 A FR0807475 A FR 0807475A FR 2940652 B1 FR2940652 B1 FR 2940652B1
Authority
FR
France
Prior art keywords
pyrazol
pyridin
derivatives
preparation
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0807475A
Other languages
English (en)
Other versions
FR2940652A1 (fr
Inventor
Jean Michel Altenburger
Valerie Fossey
Stephane Illiano
Geraldine Manette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0807475A priority Critical patent/FR2940652B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to PT98057904T priority patent/PT2382215E/pt
Priority to AU2009334570A priority patent/AU2009334570B2/en
Priority to PE2011001291A priority patent/PE20120338A1/es
Priority to BRPI0923875-1A priority patent/BRPI0923875A2/pt
Priority to MA34029A priority patent/MA32978B1/fr
Priority to SG2011047529A priority patent/SG172422A1/en
Priority to PL09805790T priority patent/PL2382215T3/pl
Priority to JP2011542887A priority patent/JP5865704B2/ja
Priority to MYPI2011003011A priority patent/MY155244A/en
Priority to EP09805790.4A priority patent/EP2382215B1/fr
Priority to KR1020117017677A priority patent/KR101630475B1/ko
Priority to EA201170900A priority patent/EA019774B1/ru
Priority to DK09805790.4T priority patent/DK2382215T3/da
Priority to SI200931025T priority patent/SI2382215T1/sl
Priority to NZ593797A priority patent/NZ593797A/xx
Priority to CN200980157589.3A priority patent/CN102333776B/zh
Priority to PCT/FR2009/052692 priority patent/WO2010076525A1/fr
Priority to ES09805790.4T priority patent/ES2511917T3/es
Priority to MX2011007061A priority patent/MX2011007061A/es
Priority to CA2748413A priority patent/CA2748413A1/fr
Priority to PA20098856101A priority patent/PA8856101A1/es
Priority to TW098145333A priority patent/TWI441828B/zh
Priority to ARP090105127A priority patent/AR074916A1/es
Priority to UY32370A priority patent/UY32370A/es
Publication of FR2940652A1 publication Critical patent/FR2940652A1/fr
Publication of FR2940652B1 publication Critical patent/FR2940652B1/fr
Application granted granted Critical
Priority to TN2011000308A priority patent/TN2011000308A1/fr
Priority to CR20110360A priority patent/CR20110360A/es
Priority to IL213790A priority patent/IL213790A/en
Priority to EC2011011164A priority patent/ECSP11011164A/es
Priority to ZA2011/04785A priority patent/ZA201104785B/en
Priority to NI201100132A priority patent/NI201100132A/es
Priority to US13/172,321 priority patent/US8697731B2/en
Priority to CO11081313A priority patent/CO6400145A2/es
Priority to HK12104300.3A priority patent/HK1163679A1/xx
Priority to US14/200,698 priority patent/US9359329B2/en
Priority to CY20141100849T priority patent/CY1115635T1/el
Priority to SM201400157T priority patent/SMT201400157B/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR0807475A 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique Expired - Fee Related FR2940652B1 (fr)

Priority Applications (37)

Application Number Priority Date Filing Date Title
FR0807475A FR2940652B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
JP2011542887A JP5865704B2 (ja) 2008-12-29 2009-12-24 ２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、この調製および治療的使用
PE2011001291A PE20120338A1 (es) 2008-12-29 2009-12-24 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparacion y su aplicacion en terapeutica
MX2011007061A MX2011007061A (es) 2008-12-29 2009-12-24 Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.
MA34029A MA32978B1 (fr) 2008-12-29 2009-12-24 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
SG2011047529A SG172422A1 (en) 2008-12-29 2009-12-24 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
PL09805790T PL2382215T3 (pl) 2008-12-29 2009-12-24 Pochodne 2-pirydyny-2-ylo-pirazol-3(2H)-onu, ich wytwarzanie i zastosowanie terapeutyczne
AU2009334570A AU2009334570B2 (en) 2008-12-29 2009-12-24 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
MYPI2011003011A MY155244A (en) 2008-12-29 2009-12-24 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
EP09805790.4A EP2382215B1 (fr) 2008-12-29 2009-12-24 Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique
KR1020117017677A KR101630475B1 (ko) 2008-12-29 2009-12-24 ２-피리딘-２-일-피라졸-３（２ｈ）-온의 유도체, 그의 제조법 및 치료 용도
EA201170900A EA019774B1 (ru) 2008-12-29 2009-12-24 Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии
DK09805790.4T DK2382215T3 (da) 2008-12-29 2009-12-24 Derivater af 2-pyridin-2-yl-pyrazol-3(2h)-on, fremstilling og terapeutisk anvendelse heraf
SI200931025T SI2382215T1 (sl) 2008-12-29 2009-12-24 Derivati 2-piridin-2-il-pirazol-3(2H)-ona, njihova priprava in njihova terapevtska uporaba
NZ593797A NZ593797A (en) 2008-12-29 2009-12-24 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
CN200980157589.3A CN102333776B (zh) 2008-12-29 2009-12-24 2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和治疗用途
PCT/FR2009/052692 WO2010076525A1 (fr) 2008-12-29 2009-12-24 Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique
ES09805790.4T ES2511917T3 (es) 2008-12-29 2009-12-24 Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y su aplicación en terapéutica
PT98057904T PT2382215E (pt) 2008-12-29 2009-12-24 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, sua preparação e sua aplicação terapêutica
CA2748413A CA2748413A1 (fr) 2008-12-29 2009-12-24 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
BRPI0923875-1A BRPI0923875A2 (pt) 2008-12-29 2009-12-24 Derivados de 2-piridin-2-il-pirazol-3 (2h)-ona, o respectivo preparo e a respectiva aplicação terapêutica.
PA20098856101A PA8856101A1 (es) 2008-12-29 2009-12-28 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparcion y su aplicacion en terapeutica
TW098145333A TWI441828B (zh) 2008-12-29 2009-12-28 ２－吡啶－２－基－吡唑－３（２ｈ）－酮衍生物、其製備及治療用途
ARP090105127A AR074916A1 (es) 2008-12-29 2009-12-28 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparacion, composiciones farmaceuticas y su uso en enfermedades cardiovasculares.
UY32370A UY32370A (es) 2008-12-29 2009-12-29 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica
TN2011000308A TN2011000308A1 (fr) 2008-12-29 2011-06-17 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
CR20110360A CR20110360A (es) 2008-12-29 2011-06-23 Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica
IL213790A IL213790A (en) 2008-12-29 2011-06-27 2-Pyridine-2-Ill-Pyrazole-3 (2 h) History - On, Preparation and Medical Use
EC2011011164A ECSP11011164A (es) 2008-12-29 2011-06-27 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica
NI201100132A NI201100132A (es) 2008-12-29 2011-06-28 Derivados de 2 - piridin - 2 - il - pirazol - 3 (2h) - ona, su preparación y su aplicación en terapéutica.
ZA2011/04785A ZA201104785B (en) 2008-12-29 2011-06-28 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one,preparation and therapeutic use thereof
US13/172,321 US8697731B2 (en) 2008-12-29 2011-06-29 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof
CO11081313A CO6400145A2 (es) 2008-12-29 2011-06-29 Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica
HK12104300.3A HK1163679A1 (en) 2008-12-29 2012-05-02 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof 2--2---3(2h)-
US14/200,698 US9359329B2 (en) 2008-12-29 2014-03-07 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof
CY20141100849T CY1115635T1 (el) 2008-12-29 2014-10-16 Παραγωγα 2-πυριδιν-2-υλο-πυραζολ-3(2η)-ονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
SM201400157T SMT201400157B (it) 2008-12-29 2014-10-29 Derivati di 2-piridin-2-il-pirazol-3(2H)-one, loropreparazione e loro uso terapeutico

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0807475A FR2940652B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2940652A1 FR2940652A1 (fr) 2010-07-02
FR2940652B1 true FR2940652B1 (fr) 2011-02-11

Family

ID=40591846

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0807475A Expired - Fee Related FR2940652B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique

Country Status (1)

Country Link
FR (1) FR2940652B1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
PE20071020A1 (es) * 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
WO2008047198A1 (fr) * 2006-10-16 2008-04-24 Pfizer Products Inc. Pyrazolyl thiénopyridines thérapeutiques
RU2009146851A (ru) * 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом

Also Published As

Publication number Publication date
FR2940652A1 (fr) 2010-07-02

Similar Documents

Publication Publication Date Title
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2915198B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2911604B1 (fr) Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
FR2926556B1 (fr) Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2915197B1 (fr) Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
FR2917412B1 (fr) Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2948939B1 (fr) Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2925902B1 (fr) DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2927625B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2947546B1 (fr) Derives de pyrazoles, leur preparation et leur application en therapeutique
FR2930249B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2892416B1 (fr) Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2932481B1 (fr) Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2906251B1 (fr) Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique
FR2911605B1 (fr) Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
FR2919610B1 (fr) Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160831